AC
ACRS icon

AXQ Capital’s Aclaris Therapeutics ACRS Stock Holding History

AXQ Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,186
Closed -$72.8K – 981
2025
Q4 		$72.8K Buy
24,186
+10,217
+73% +$25.8K 0.02% 677
2025
Q3 		$26.5K Buy
+13,969
New +$24.4K 0.01% 548
2023
Q2 		– Sell
-25,816
Closed -$209K – 266
2023
Q1 		$209K Buy
+25,816
New +$328K 0.08% 398

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

AXQ Capital's ACRS Position: Q1 2026 in Review

AXQ Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 24,186 shares — an estimated $72.8K sold.

AXQ Capital first reported a position in ACRS in Q1 2023 and held it in 3 quarters. The position peaked at $209K in Q1 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • AXQ Capital reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AXQ Capital sold 24,186 Aclaris Therapeutics shares in Q1 2026, an estimated $72.8K.
  • AXQ Capital first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 3 quarters.
  • AXQ Capital's Aclaris Therapeutics position peaked at $209K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.